Head neck cancer new drug development progress
Head neck cancer new drug development progress
Clinical trial for head neck cancer (Project ID: LUKACT-01-01; Project title: Study on the use of activated T cells for the treatment of locally advanced head neck squamous cell carcinoma after surgery section and combined radiotherapy and chemotherapy) was approved by TFDA in 2018. We enrolled the first volunteer in Taipei Veterans General Hospital. This trial is currently undergoing a protocol amendment.
| Treatment |
Drug discovery
|
preclinical research
|
phase I
|
phase II
|
phase III
|
NDA/Approved |
| Activated T cell injection |
🔵 | 🔵 | 🔵 | 🔵 |
|
📋Clinical Trial Name
Study on the use of activated T cells for the treatment of locally advanced head neck squamous cell carcinoma after surgery section and combined radiotherapy and chemotherapy.
| Trial Applicant | Lukas Biomedical Inc. |
|---|---|
| Trial Sponsor | Same as the trial applicant |
| Trial Protocol Number | LUKCT-01-01 |
| Approval Document Number | 1066038845 |
| Approval Registration Date | 27 April 2018 |
| Estimated Trial Period | 1 December 2021 to 31 December 2026 |
Trial Objectives
To evaluate the safety and immune cell expression change of autologous peripheral blood-derived activated T cells used for the treatment of locally advanced head and neck squamous cell carcinoma.
Trial Phase
Phase Ⅱ
Drug Name
Activated T cell
Proposed IndicationsHead and Neck Cancers
